Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 8Gastrointestinal 8Endocrine 8CNS 1

Conditions

Paraganglioma 6Meningioma 6Pheochromocytoma 5Neuroendocrine Tumors 4Neuroblastoma 3Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Sarcoma, Synovial 1Recurrence 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Hypertension 1Gastro-enteropancreatic neuroendocrine tumor 1Esthesioneuroblastoma, Olfactory 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Medullary 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1amino-acid, glucose, and electrolyte solution 1PM 01183 1Lutetium-177 1Lutetium 1Irinotecan 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × lutetium Lu 177 dotatate × CNS × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡